ADAM = a disintegrin and metalloprotease; AKT = protein kinase B; AR = amphiregulin; EGF = epidermal growth factor; EGFR = epidermal growth factor receptor; GPCR = G protein coupled receptor; HB-EGF = heparin-binding epidermal growth factor; IGFR = insulin-like growth factor receptor; MAPK = mitogen-activated protein kinase; MMP = matrix metallo protease; TACE = tumour necrosis factor α-converting enzyme; TGFα = transforming growth factor α.
Introduction
Epidermal growth factor receptor (EGFR) comprises a dominant signalling pathway for many tumours. In breast cancer, increased expression of EGFR or its EGF-like ligands and hyperactivation of subsequent mitogen-activated protein kinase (MAPK) and protein kinase B (AKT) signalling have been linked to anti-hormone resistant growth, metastatic progression and poor prognosis. Considerable data exist detailing EGFR activation and the downstream signalling that is triggered subsequent to EGFR ligand binding, allowing rationale design of several anti-EGFR agents that are currently in clinical trials in cancers including the breast. However, less is known about the mechanisms regulating EGF-like ligand availability and their potential as therapeutic targets.
EGFR ligands, including transforming growth factor α (TGFα), heparin-binding EGF (HB-EGF) and amphiregulin (AR), are expressed as transmembrane precursors. These are released from the cell surface following shedding of the extracellular domain (ectodomain shedding) by zincdependent proteinases. The soluble ligand can bind and activate EGFR in an autocrine or paracrine manner, while the transmembrane (pro) form may activate EGFR in adjacent cells (juxtacrine). Of emerging importance as regulators of EGFR ligand shedding is the ADAM (a disintegrin and metalloprotease) family of membrane glycoproteins. This family currently comprises 34 members. However, the nature of individual ADAMs required for EGFR ligand shedding, and their role in EGFR activation and its interaction with other signalling pathways, remain poorly defined in tumour cells. Three new articles examining ADAM17 (TNFα-converting enzyme; TACE) and ADAM10 (Kuzbanian) shed light in these areas. Borrell-Pages et al. [1] establish relevance of TACE to TGFα shedding and EGFR signalling in clinical breast cancer, while Gschwind et al. [2] and Yan et al. [3] reveal that TACE and ADAM10 contribute to the interplay between EGFR and diverse signalling pathways.
ADAM metalloprotease TACE controls TGFα α shedding in tumours in vivo and associates with EGFR activation in breast cancer
The new article by Borrell-Pages et al. provides compelling evidence that EGFR activation by TGFα is critically dependent on ligand shedding in tumours. Interestingly, shedding not only controls availability of the soluble ligand but also determines juxtacrine activity of the transmembrane form. The ADAM TACE was revealed to be the key regulator for TGFα shedding in transfected Chinese hamster ovary (CHO) cells. These data complement previous in vitro observations that absence of/non-functional TACE underlies defective TGFα shedding. Excitingly, Borrell-Pages et al. demonstrated a crucial role for TACE in tumourigenesis, with TACE-mediated TGFα shedding being essential for EGFR activation and maximal tumour development of the transfected CHO cells in vivo. Furthermore, TACE was markedly overexpressed in human breast cancer, where it directly associated with EGFR activation. TACE thus appears to be of considerable importance in regulating EGFR signalling in breast tumours. The prognostic implications of heterogeneity of TACE expression remain to be addressed. Similarly, monitoring of TACE in endocrine resistant breast cancer and clinical progression is required, particularly since metalloprotease-mediated EGFR ligand shedding regulates breast cancer cell proliferation and migration in vitro [4] . those employing metalloprotease-mediated shedding of EGFR ligands. G protein-coupled receptors (GPCR) transactivate EGFR in diverse cells, an interplay previously thought to be largely EGFR ligand-independent. However, building on observations that GPCR can also transactivate EGFR via metalloprotease induction of EGF-like ligands in several tumour cell types, Yan et al. have discovered that ADAM10 promotes HB-EGF release in COS-7 and PC3 cancer cells. In parallel, Gschwind et al. have demonstrated in head and neck cancer cells that GPCR transactivation of EGFR is regulated by TACE cleavage of AR, resulting in MAP kinase and AKT signalling, proliferation and cell migration. Interestingly, metalloproteasemediated GPCR-EGFR cross-talk has also been reported in breast cancer [5] . Thus, oestrogens rapidly transactivate EGFR to hyperactivate MAP kinase via G protein coupled receptor (GPR30)-dependent promotion of HB-EGF at the plasma membrane, an event that occurs in oestrogen receptor positive and negative breast cancer cells [5] . Of some further interest is insulin-like growth factor receptor (IGFR), which induces EGFR activation via metalloprotease-dependent release of AR or HB-EGF in several tumour cell types [6] . IGFR-EGFR cross-talk is certainly apparent in mammary epithelial cells, since EGFR blockade abrogates IGFR-driven MAP kinase signalling and primes apoptosis. However, it remains controversial whether this cross-talk involves metalloprotease-mediated EGFR ligand release [7] and studies investigating IGFR-EGFR interactions are ongoing in breast cancer. While the matrix metalloproteases MMP2 and MMP9 appear to play a role in GPCR-mediated HB-EGF release, the full profile of metalloproteases, including ADAMs, contributing to EGFR transactivation and its end-points remains to be defined in breast cancer. While their individual signalling role and cellular impact remains to be defined, an increasing cohort of ADAMs are prominent in breast tumours. Borrell-Pages et al. also detected ADAM10 within normal and cancerous breast, while ADAM12 is overexpressed in several breast cancer cell lines [8] and ADAM9 is enriched in node positive disease [9] . Thus, given the prevalence and emerging signalling importance of ADAMs in breast cancer, ADAMmediated ligand shedding may provide interesting new avenues for therapeutic exploitation to abrogate EGFR signalling, particularly since it is now clear that EGFR inhibition has considerable potential to uncouple diverse mito-genic inputs. Such therapies may confer important advantages over existing anti-EGFR strategies, since ADAMmediated ectodomain shedding regulates many additional proteins linked to signal transduction and neoplastic cell behaviour. Thus, ADAMs can cleave cytokines, receptors (erbB4, MET, NGFR, PDGFR, TNFR, IL receptor), additional ligands (neuregulins), IGF binding proteins, and NOTCH signalling elements [10] . Future development of ADAM-selective inhibitors will be essential if unwanted side effects, previously noted with broad-spectrum metalloprotease inhibitors, are to be avoided.
Conclusion

